| European Case Law Identifier: | ECLI:EP:BA:2013:T142212.20130411 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 11 April 2013 | ||||||||
| Case number: | T 1422/12 | ||||||||
| Application number: | 07776245.8 | ||||||||
| IPC class: | C07C 237/26 C07C 231/24 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Tigecycline crystalline forms and processes for preparation thereof | ||||||||
| Applicant name: | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | ||||||||
| Opponent name: | - | ||||||||
| Board: | 3.3.10 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Inventive step (yes): (re)formulation of technical problem allowable - any effects may be taken into account, so long as they concern the same field of use and do not change the character of the invention Specific crystalline form of tigecycline non-obvious over amorphous form in view of the unexpected improvement in stability with respect to epimerisation specific to this type of tetracycline antibiotic |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t121422eu1.html
Date retrieved: 17 May 2021